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1  | INTRODUC TION
Innate immunity not only represents the first line of defence against in-
vading microbial pathogens but also is the first step towards the activa-
tion and stimulation of adaptive immunity. Upon exposure to bacteria, 
viruses, protozoa and fungi, innate immune cells including neutrophils, 
monocytes, macrophages, dendritic cells (DCs), natural killer (NK) cells 
and the complement system are activated. The response of the innate 
immunity to microbial pathogens relies on the specific host-recep-
tor detection of pathogen- and danger-derived molecular signatures, 
known as PAMPs and DAMPs, respectively. When PAMPs and DAMPs 
are recognized by germline-encoded pattern-recognition receptors 
(PRRs), different types of cytokines would be released, which in turn 
attract secondary defensive immune cells. In the long list of PRRs, Toll-
like receptors (TLRs) are the most important ones. TLRs are one of the 
largest and most well-studied families of PRRs, which were first rec-
ognized in the fruit fly, Drosophila melanogaster.1 Not only these re-
ceptors are one of the main components of innate immunity, infection 
diseases, and inflammatory conditions, but also they act as a bridge 
between innate and adaptive immunity. Apart from regulatory role in 
immune responses, TLRs have a hand in tissue homeostasis mainte-
nance by regulating tissue repair and regeneration. But the mystery 
behind TLR functions in the cells was not limited only to these findings, 
and there was some evidence supporting the fact that they might have 
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In the dark path of tumorigenesis, the more carefully the cancer biology is studied, 
the more brilliant answers could be given to the countless questions about its or-
chestrating derivers. The identification of the correlation between Toll-like recep-
tors (TLRs) and different processes involved in carcinogenesis was one of the single 
points of blinding light highlighting the interconnection between the immune sys-
tem and cancer. TLRs are a wide family of single-pass membrane-spanning receptors 
that have developed through the evolution to recognize the structurally conserved 
molecules derived from microorganisms or damaged cells. But this is not everything 
about these receptors as they could orchestrate several downstream signalling path-
ways leading to the formation or suppression of cancer cells. The present review is 
tempted to provide a concise schematic about the biology and the characters of TLRs 
and also summarize the major findings of the regulatory role of TLRs and their associ-
ated signalling in the pathogenesis of human cancers.
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other roles in the cells. The results of molecular investigations shed 
light on the ability of TLRs in propagating specific signalling in the cells 
which regulates the balance between pro- and anti-apoptotic target 
genes.2 Having established these regulatory functions, a new chapter 
has opened about the TLRs, introducing them as important regulators 
of tumorigenesis.
2  | A GLIMPSE INTO THE BIOLOGY OF 
TLRs ,  FROM THEIR BIOGENESIS TO THE 
DEPTH OF THEIR FUNC TIONS
From the immunological point of view, the characteristics of these 
molecules have been well-studied in different reports to unveil the 
structure, signalling and functions of TLRs in cells. The results of high-
resolution X-ray crystallography analysis have revealed that TLRs devi-
ate considerably from the canonical LRR structure and thereby they 
could interact with a wide range of ligands in a highly divergent fash-
ion. This different structure gives TLRs the ability to be activated in 
a different manner from other LRRs, resulting in the involvement of 
these receptors in other biological processes rather than only regulat-
ing innate immunity.3 In the following part of this article, we take a 
look at the biogenesis of TLRs to become more aware of their unique 
biology. Then, a brief explanation would be provided about their struc-
ture, their probable ligands and downstream signalling pathways. As 
the propagation of the TLR cascade may result in the regulation of di-
verse intracellular functions, we dedicate the last part of this section to 
explain the biological functions of the molecules so that we can learn 
more deeply about the functions of TLRs.
2.1 | A glance at TLR biogenesis and localization
All the TLRs are synthesized from their mRNAs into functional con-
figurations in the endoplasmic reticulum (ER) and are translocated 
to the Golgi complex followed by trafficking to either the plasma 
membrane or endosomes. The localization of TLRs is a complicated 
process, which is controlled by a group of ER-associated proteins. 
Thus far, ten functional TLRs have been identified in humans ac-
cording to their subcellular localization. Although TLR1, TLR2, TLR4, 
TLR5, TLR6 and TLR10 are expressed on the cell surface and migrate 
to phagosomes after activation, the expression site of TLR3, TLR7, 
TLR8 and TLR9 is in intracellular compartments, in particular the en-
dosomes and the endoplasmic reticulum. Among all, the subcellular 
localization of TLR4 is unique as this TLR could be found either at the 
plasma membrane or at endosomal vesicles.4
A member of the ER-resident HSP90 protein family, gp96, serves 
as a general chaperone for the surface-expressed TLR1, TLR2, TLR4 
and TLR5, and intracellular TLR7 and TLR9. Deficiency in gp96 leads 
to the loss of expression of TLR1-TLR5 and TLR7 or improper TLR9 
protein folding.5 Unc-93 homolog B1 (UNC93B1), a multi-pass TM 
protein, controls the endosomal trafficking of TLRs, especially TLR3. 
For endosomal TLRs, such as TLR3, TLR7 and TLR9, a multi-span 
transmembrane protein, UNC93B, enters the game to traffic these 
proteins to endosome.4 Another ER-resident protein that regulates 
the trafficking of TLRs is named protein associated with TLR4 A 
(PRAT4 A), which on one hand guide TLR1, TLR2 and TLR4 to the 
cell membrane, and on the other hand propel TLR7 and TLR9 to en-
dosomes.6 TLRs tend to construct dimers in the presence of ligand. 
Most of the TLRs appear to form homodimers; however, the story is 
quite different for TLR2 as it prefers to be presented as a heterodi-
mer with either TLR1 or TLR6.
2.2 | A glance at TLRs structure
TLRs belong to type I transmembrane glycoproteins and contain 
three major domains, ectodomain, single-spanning transmembrane 
domain and cytoplasmic TLR domain. The ectodomain is oriented 
towards extracellular space or luminal space (depending on recep-
tor localization) and contains multiple7-19 leucine-rich repeats (LRRs) 
that harbour 24-29 amino acids.20 Two types of motifs were consid-
ered for this domain: ‘typical’ (‘T’) motifs (LxxLxLxxNxLxxLxxxxF/
LxxLxx) and ‘bacterial’ (‘S’) motifs (LxxLxLxxNx LxxLPx(x)LPxx).20 
The unique horseshoe shape of the TLRs is established by fold-
ing LRR modules into parallel β-sheets and α-helix that bend into 
a concave surface.21 Moreover, as LRR hydrophobic residues are 
packed within the interior of the ectodomain structure and forming 
a ligand-binding hydrophobic pocket, it is suggested that LRRs play 
a pivotal role in recognition and binding of pathogens. In addition, 
the C-terminal of LRRs controls receptor dimerization and signal 
transmission. The next domain of TLRs is the single-spanning trans-
membrane domain that is homologous to IL-1R analogue and anchors 
the receptor in the correct orientation on the cell membrane. The 
third and the last domain in the structure of TLRs is the cytoplasmic 
TLR domain (Toll/interleukin-1 receptor domain, TIR domain) that 
is usually composed of approximately 150 amino acid residues.21 
Upon ligand-ectodomain interaction and respective alterations in 
the receptor conformation, TIR domain dimerizes either in the form 
of hetero- or homodimers and initiates specific signalling pathway 
through engaging of a wide range of adaptor proteins that all contain 
TIR domain, including MyD88, TIRAP/MAL, TRIF, TRAM and SARM. 
All TLRs, except TLR3, utilize MyD88 for signal transduction upon 
ligand binding, whereas TLR3 signals through the adaptor TRIF. It 
should be noted that the dimerization of the TIR domain is necessary 
for the dimerization of the cytoplasmic domain.22
2.3 | A glance at TLRs ligands
Although each TLR recognizes distinct ligands, the mechanisms 
of TLR activation and signal transduction are somehow the same. 
Several microbial ligands have been enumerated for TLRs, which 
their lists are summarized in Table 1. Microbial ligands are not the 
only stimulators of TLRs, and recently, a group of other proteins, re-
ferred to as alarmin, have been identified. They could propagate TLR 
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signalling in the cells, especially through activating TLR2 and TLR4. 
The list of these endogenous ligands is also summarized in Table 1. 
According to the surveillance model proposed by Johnson et al, an-
other sort of ligands that are responsible for TLR activation is known 
as the degradation products of endogenous macromolecules, such 
as heparan sulphate and polysaccharide fragments of hyaluronan.23 
The signals that are mediated by the degenerated macromolecules 
mostly trigger TLRs-mediated tissue repair processes in addition to 
initiating protective inflammatory responses.24
2.4 | TLR signalling
Given the importance and the key roles of TLRs in regulation of im-
mune responses, it is not surprising that their emitted signals are a 
succession of complex events in the cells that lead to activation or 
suppression of a wide range of downstream signalling axes. Generally 
speaking, the TLR signalling pathway could be mediated through either 
MYD88-dependent or MYD88-independent manner. The TLR signal-
ling has been well reviewed in an article provided by Luo et al22
2.5 | TLR functions: from immunological 
perspective to non-canonical functions
2.5.1 | Immunological functions of TLRs
Innate immune responses
When it comes to TLRs, the first thing that comes to mind is its bona 
fide action in response to specific molecules derived from bacteria 
and viruses.24 In the perspective of innate immunity, which TLRs 
endow their popularity from, these receptors play a fundamental 
role in phagocytosis of microorganisms and propagation of microbial 
killing through elevating the production of reactive oxygen and ni-
trogen intermediates. Moreover, the interaction of TLRs with their li-
gands could attract leucocytes to the infected organs either through 
regulating the surface expression of adhesion molecules or by induc-
ing specific chemokines. Notably, TLRs also regulate the functions of 
potent antimicrobial factors, such as defensins (α and β), phospholi-
pase A2, lysozyme and the regeneration (Reg) family of molecules.11
Adaptive immune responses
TLRs are indeed the main players of the innate immunity system; 
however, their central role in regulation of host protective adaptive 
immune responses should not be underestimated. It has been sug-
gested that TLRs could stimulate both T cell- and B cell–mediated 
immune responses upon exposure to adjuvants containing microbial 
lysates or products.11 Moreover, TLRs could stimulate professional 
antigen-presenting cells (APCs) and have a role in processing and 
presentation of microbial antigens, up-regulation of co-stimulatory 
molecules, T cell activation and suppression of regulatory T cells.12 
TLR-mediated production of IL-12 dictates differentiation of acti-
vated T cells into T helper 1 (Th1) cells. TLRs are also crucial for ac-
tivation and maturation of the B cell responses during infection and 
vaccination. Last but not least, through both T cell–dependent and 
T cell–independent pathways, TLRs regulate B cell proliferation, im-
munoglobulin isotype class switching and somatic hypermutation.13
2.5.2 | Non-canonical functions of TLRs
Apart from participation in the regulation of immune responses, 
which is well-described in the previous reports, TLRs have some 
TA B L E  1   List of ligands that could activate TLRs
DAMPs PAMPs References
TLR1 β-defensin 3 Lipoarabinomannan (mycobacteria), triacyl lipoproteins, 
peptidoglycan (Gram-positive bacteria), zymosan 
(fungi)
85,86
TLR2 Heat-shock protein 60 (HSP60), HSP70, HSP96, high-
mobility group protein B1 (HMGB1), hyaluronic acid, 
human cardiac myosin and biglycan
Lipoprotein (bacteria), peptidoglycan (Gram-positive 
bacteria), lipoteichoic acid (Gram-positive bacteria), 
lipoarabinomannan (mycobacteria) and zymosan 
(fungi)
86-88
TLR3 mRNA Viral dsRNA (WNV, RSV) 88
TLR4 HSP22, HSP60, HSP70, HMGB1, fibronectin, 
fibrinogen, hyaluronic acid, heparan sulphate and 
biglycan
LPS (Gram-negative bacteria) and envelope proteins 
(MMTV and MMLV)
7,8
TLR5 Flagellin (bacteria) 87
TLR6 Diacyl lipopeptides (mycoplasma), peptidoglycan 
(Gram-positive bacteria) and zymosan (fungi)
87,88
TLR7 Endogenous RNA Viral single-stranded RNA (ssRNA) 9
TLR8 Endogenous RNA Viral single-stranded RNA (ssRNA) 9
TLR9 Endogenous DNA Unmethylated CpG motifs (bacteria and viruses) and 
haemozoin (plasmodium)
9,10
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non-canonical functions in tissue repair, regulation of apoptotic 
cell death and autophagy. Any aberrancy in the regulation of 
these receptors could orchestrate the initial step of tumour de-
velopment, endangering normal human cells to form cancer cells 
(Figure 1).
Tissue repair
Several mechanisms have been enumerated for TLRs through 
which they could induce tissue repair and regeneration upon an 
injury. Generally, participation of TLRs in wound healing occurs 
at both early and delayed stages. Although at the early phase of 
wound healing TLRs recruit inflammatory cells to the injured site 
to produce cytoprotective signals through up-regulating the ex-
pression of anti-apoptotic genes, these receptors could modulate 
fibroblast recruitment and regenerative responses at the delayed 
phase. TLR4 could also increase epithelial cell life span and prevent 
the migration of keratinocytes.14 TLR3, as an endosomal TLR, par-
ticipates in delayed wound healing that is mainly mediated through 
TRIF-dependent type I-IFN secretion. Of note, several studies also 
declared that TLRs can regulate extracellular matrix (ECM) metabo-
lism by increasing the production of MMPs, such as MMP1, MMP3 
and MMP9.15
Autophagy
When it became evident that activated TLR4 could enhance au-
tophagic elimination of phagocytosed mycobacteria in macrophages 
via VPS34-dependent formation of cytoplasmic LC3 aggregates, a 
new chapter has been opened in the biology of TLRs in the regula-
tion of autophagy. It did not take long that the role of other TLRs in 
the regulation of autophagy has been established. TLR7 can elimi-
nate bacillus Calmette-Guerin (BCG) through up-regulation of ATG5 
and Beclin-1.16 TLR2 eradicates Listeria monocytogenes through 
ERK-mediated activation of autophagy. The more carefully the as-
sociation of TLRs with the process of autophagy is studied, the more 
molecular mechanisms have been found to explain the precise role 
of this cascade in the activation of this self-devouring event. It turns 
out that TLRs could recruit Beclin-1, which in turn interacts with 
TRAF6, inducing K63-polyubiquitination of the BH3 domain for its 
activation and subsequent formation of autophagosomes.17
3  | TLRs IN C ANCER: DOUBLE-EDGED 
SWORDS
The first evidence supporting the involvement of TLRs in the tumo-
rigenesis event has stemmed from a report indicated that the risk of 
cancer development is significantly higher in organs that are directly 
or indirectly exposed to bacterial TLR ligands. This finding is also 
reflected in the low incidence of cancer development in germ-free 
animals.18 Although there remains much to learn about the involve-
ment of TLRs in tumorigenesis, a question has occupied the mind 
of the researchers: How TLRs___that are responsible for the regula-
tion of immune responses against unknown antigens, such as cancer 
cells___could play such a controversial mechanism of action? The an-
swer to this question may be in the amplitude and length of recep-
tor activation. Although chronic low-grade TLR activation favours a 
tumour-promoting pro-inflammatory state, high-dose TLR activation 
induces antitumour response.19
3.1 | The pro-tumour activity of TLRs
The idea behind the involvement of TLRs and their related signalling 
in the formation of human cancers has originated from the consider-
able number of studies reported the abnormal expression of TLRs on 
tumour cells, where they may influence tumour growth and immune 
responses.25 The discovery of these receptors in tumour cells has 
heralded a renaissance in the interconnection between innate im-
munity and tumour biology.
3.1.1 | Overexpression of TLRs in human cancers
Each TLR, either as a single-player or as a team, could participate 
in the development of a specific type of tumour. When it comes 
to oral and gastrointestinal cancers, the first TLR that comes to 
mind is TLR2.26 TLR3 has shown to participate in the pathogen-
esis of neuroblastoma, breast adenocarcinoma, hepatocellular, 
papillary thyroid, nasopharyngeal and lung carcinomas.27 TLR4 is 
notorious for its fundamental participation in the pathogenesis of 
human lung cancer, neuroblastoma, colorectal cancer and thyroid 
carcinomas.2 Various levels of TLR9 expression have been demon-
strated in tumour specimens from patients with prostate cancer, 
breast cancer, astrocytoma, lung cancer and glioblastoma.28 The 
involvement of TLR9 could be used as a risk stratification factor to 
categorize the cancer patient's prognosis and outcome; however, 
based on the type of cancer, it may be either attributed to the 
good or attributed to the poor prognosis. In renal cell carcinoma, 
mucoepidermoid salivary gland carcinoma and pancreatic cancer, 
the higher expression levels of TLR9 are indicative of a longer sur-
vival.29 However, the up-regulation in TLR9 in oesophageal adeno-
carcinoma, squamous cell carcinoma of the tongue and prostate 
cancer is related to the more aggressive form of the disease and 
the dismal outcome.30
So far, we have looked at the association between the individ-
ual TLRs and the induction of human cancers; however, in most 
cases, these receptors act as a group to enhance the survival and 
proliferative capacity of the tumour cells. TLR4 and TLR9 could 
endow prostate cancer cells the ability to proliferate more aggres-
sively.31 TLR9 and TLR5 could also make a team in the formation of 
cervical carcinogenesis, as there are some reports demonstrating 
that expressions of these TLRs are gradually increased during the 
progression of low-grade cervical intraepithelial neoplasia (CIN) to 
high-grade CIN and then to invasive cervical squamous cell car-
cinoma.32 Other examples of simultaneous expression of TLRs 
in cancer cells could be found in ovarian cancer cell lines which 
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displayed overexpressed TLR2-TLR5,33 and in lung cancer with 
overexpressed TLR2-TLR4 and TLR9.34 Moreover, overexpression 
of TLR4, TLR5 and TLR9 not only has been reported in gastric can-
cer cell lines but also was observed in the metaplastic and dys-
plastic gastric epithelial cells of patients with Helicobacter pylori 
gastritis.35 One of the human cancers which displayed the overex-
pression of multiple TLRs is melanoma, in which up-regulation of 
TLR2-TLR4 is coupled with metastasis and tumour progression.36 
The association between the overexpression of TLRs and human 
cancers is summarized in Table 2.
Another critical complication that is associated with grouped TLRs 
expression is the regulation of drug-resistance phenotype, which 
eventually lead to the poor outcome of patients and even increase 
the risk of cancer recurrence. Co-expression of TLR1, TLR7 and TLR9 
in myeloma cells has shown to be involved in induction of drug re-
sistance.37 Moreover, the up-regulation of TLR3, TLR4 and TLR9 ex-
pressions could increase the probability of biochemical recurrence 
and cancer metastasis in prostate and breast cancer, respectively.38 
TLR4 and TLR9 could also orchestrate a signal that helps cancer cells 
to bypass the immune responses by increasing the expression of im-
munosuppressive cytokines and anti-apoptosis proteins. It has been 
also indicated that the co-stimulation of TLR7 and TLR8 could induce 
chemo-resistance via NF-κB–mediated up-regulation of anti-apop-
totic members Bcl-2 family in human lung cancer cells.39
3.1.2 | The mechanisms through which 
TLRs orchestrate pro-tumour responses
The aberrant overexpression of TLRs on malignant cells and their 
well-established association with the promotion of human cancers 
has put an end to the multiple questions wondering the role of TLRs 
in the regulation of tumorigenesis, especially at the early stage of the 
event. This causes the new stream of attempts to be accomplished 
for proposing the probable mechanisms through which TLRs could 
promote carcinogenesis (Figure 2).
F I G U R E  1   Non-canonical functions of TLRs. TLRs play an important role in wound healing and tissue repair. TLR4 signalling inhibits 
migration of keratinocytes and its expression on epithelial cells results in an increased survival. Stimulation of TLR7, TLR8 and TLR9 have 
also anti-apoptotic effects on fibroblasts through induction of type I interferons. In addition, TLRs can regulate wound healing response by 
attenuating fibroblast migration and increasing MMPs. Control and regulation of autophagy are another physiological function of TLRs. TLR4 
signalling leads to LC3 aggregation via the TRIF signalling pathway which engages VPS34. Autophagic elimination of BCG can be triggered by 
TLR7 which uses the MyD88 signalling pathway to recruit Beclin-1 and ATG5. TLR2 activation cascade also results in ERK phosphorylation, 
which in turn leads to the formation of the LC3 complex that is needed for listeria monocytogenes autophagic elimination
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TA B L E  2   The association between the overexpression of TLRs and the development of human cancers
Up-regulated TLRs Outcome References
Ovarian cancer TLR4
TLR2-TLR5
Recruits PI3K axis to increase XIAP leading to tumour growth and 
chemo-resistance
Inhibit apoptosis by increasing XIAP expression and Akt phosphorylation
33
Myeloma cells TLR1, TLR7, TLR9 Prevent apoptosis through autocrine secretion of IL-6 and induction of drug 
resistance
37
Breast cancer TLR3, TLR4, TLR 9 Induce tumour metastasis through increasing of MMP13 and lipid 
peroxidation
70
Prostate cancer TLR9 Induces metastasis through increasing MMP13 expression
Enhancing cell survival and proliferation by activation of NF-κB and c-Myc
55
Melanoma TLR2, TLR3, TLR4 Induce metastasis through increasing MMP13
Up-regulation of pro-inflammatory cytokines and chemokines, 
immunosuppressive cytokine
36,56
Gastric cancer TLR2, TLR9
TLR4, TLR5, TLR9
TLR2
Induce angiogenesis through elevation of COX-2 and PGE2 expression
Induce NF-κB–dependent tumour invasion and metastasis





Induces angiogenesis through elevating COX-2 and PGE2, as well as 
phosphorylation of EGFR




Immune escape via secretion of IL-6, IL-8, VEGF and GM-CSF and drug 
resistance
Induces metabolic reprogramming by increasing HIF-1α
69,89
Colon cancer TLR4 Apoptosis inhibition; relapse and metastasis 90
Pancreatic cancer TLR2, TLR4, TLR9 Increase VEGF, PDGF, MAPK and pERK leading to inflammation and 
angiogenesis
91




Resistance to TNF-α or TRAIL-induced apoptosis through NF-κB 
up-regulation
Induces metastasis
Increase the expression of Bcl-2 by activating NF-κB
Increases tumour cells proliferation and IL-8
34





Up-regulates the proliferative kinase ERK & reduce pro-apoptotic caspase-3 
activity
Induce metabolic reprogramming by increasing HIF-1α
Induce tumour invasion and metastasis
92
Bladder cancer TLR2, TLR3, TLR4 Enhance transcription of genes involved in cell proliferation through 
activation of NK-κB
Induction of pro-inflammatory and angiogenic factors such as COX-2, VEGF 
and TGF-β






Increases cell proliferation and survival through the NK-κB and MAPK 
pathways
Increases pro-inflammatory factors like COX-2 and prostaglandin through 
the STAT3 pathway
Anti-apoptotic effects by inhibition of caspase 3, 6, 7 and 9 transcription
Increases tumour invasion and metastasis, especially macrovascular 
invasion





TLR3, TLR4, TLR7, TLR9
Immune escape and inflammation by up-regulation of IL-8 and COX-2
Tumour metastasis via up-regulation of p38 and selectin





TLR2, TLR4 Induction of inflammation via up-regulation of TNF-α, IL-6 and IL-8 97
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TLR-mediated inflammation
In 2000, Hanahan and Weinberg proposed a model to define ‘six 
hallmarks’ that a tumour requires for maintaining its survival.40 
However, as the conventional knowledge about the pathogenesis 
of cancer was progressing, inflammation was also added as the 
seventh feature to the list.41 There are a considerable number of 
studies with the focus on the correlation between cancer develop-
ment and the previous history of microbial infection, injury, inflam-
mation and tissue repair. Although it is early to hazard a conjecture 
for the mechanism through which inflammation may develop a 
malignancy, the possible candidate could be TLRs that engage in a 
unique cross-talk with the NF-κB signalling axis. Through regulating 
more than a hundred pro-inflammatory genes, NF-κB is a master 
of inflammation regulator.42 When TLR signalling is stimulated, it 
recruits the NF-κB signalling axis to increase the expression of in-
flammatory cytokines, such as interleukin (IL)-1β, tumour necrosis 
factor α (TNF-α) and IL-6.42 These cytokines are notorious for their 
role in the induction of cancer in the intestine, liver, stomach and 
skin.43 Apart from regulation of pro-inflammatory cytokines, TLR-
mediated activation of the NF-κB signalling axis also regulates a 
wide variety of intracellular responses, including cell proliferation, 
anti-oxidant defence and prevention of apoptosis in the malignant 
cells.44 The association between TLRs and inflammatory responses, 
indeed, makes a vicious cycle; the chronic inflammation induces 
oxidative stress, leading to the formation of oxidized lipids, which 
by their deformed patterns act as DAMPs to re-activate a group 
of TLRs.
TLR-mediated anti-apoptotic effects
As mentioned earlier, the TLR network has a tight cross-talk with 
the NF-κB axis through either MYD88-dependent or MYD8-
independent manner.44 As such, TLR-induced NF-κB activation in-
hibits apoptosis and promotes tumour cell survival in colon cancer, 
liver cancer, stomach cancer and lung cancer.39,45 Independent of 
the NF-κB axis, it has been claimed that the excessive expression 
of TLR4 on tumour cells blocks the cytotoxic effects of T lympho-
cytes and enhances the growth of the tumour in vivo.46 In a study in 
ovarian cancer cells, Kelly et al showed that the activation of TLR4 
signalling promotes tumour growth and induces chemo-resistance 
through recruiting the PI3K signalling axis, which in turn increases 
the expression of X-linked inhibitor of apoptosis (XIAP) in the malig-
nant cells.47 The oncogenic effect has also been reported for TLR7 
and TLR9 in the myeloma cells, where the aberrant expression of 
such receptors prevents chemotherapy-induced apoptosis through 
promoting the autocrine secretion of IL-6.37,48 Besides, it has been 
revealed that the inhibition of TLR4 using small molecule inhibitor 
TAK-242 suppressed NF-кB–related anti-apoptosis genes BCL-xL, 
BCL-2 and survivin in breast and ovarian cancer cells and led to in-
creased apoptosis.49,50
In a recent study, we also examined the combination of TAK-242 
and four well-known chemotherapeutic agents: paclitaxel, cisplatin, 
doxorubicin and arsenic trioxide in breast and ovarian cancer cells. 
Interestingly, we realized that the inhibition of TLR4 boosted the cell 
cytotoxicity of all drugs, which indicates the fact TLR4 would confer 
chemo-resistance to a broad range of anti-cancer agents.51,52
F I G U R E  2   The mechanisms through which TLRs orchestrate pro-tumour responses. TLR stimulation activates the NF-κB cascade, which 
in turn increases the transcription of inflammatory cytokines including IFN-α, IL-1 and IL-6. Activation of the NF-κB axis not only promotes 
anti-apoptotic factors (Bcl-XL, Bcl-2, survivin) but also up-regulates MMPs which are responsible for the degradation of extracellular matrix. 
Although TLR4 activation leads to the production of MMP2 and β1-integrin overexpression, TLR9 stimulation enhances MMP13 level in 
breast cancer. As represented, increasing of PG-E2 and COX-2 by TLR2, TLR4 and TLR9 and phosphorylation of EGFR by TLR4 are the most 
important mechanisms in TLR-mediated angiogenesis. Stimulation of TLRs in the tumour microenvironment can provoke tumour cells or 
tumour-infiltrating cells to produce suppressor cytokines and chemokines which not only suppress immune cells but also attract more cells 
to tumour microenvironment—such as MDSC, TAMs and CAFs—to fulfil tumour needs. Finally, TLR downstream signalling can make tumour 
cells and tumour-infiltrating cells to switch their metabolic pathway from oxidative phosphorylation to glycolysis
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TLR-mediated invasion and metastasis
Having established the role of TLR-associated signalling pathways 
in multiple steps of tumorigenesis, intense interest has been at-
tracted to investigate whether this network could also participate in 
tumour cell invasion and metastasis. In similarity with other stages 
in tumorigenesis, the results of two studies showed that TLR activa-
tion in tumour cells increases the tendency of tumour cells to adhere 
to the extracellular matrix and endothelial cells, which ultimately 
elevates the risk of tumour metastasis. It has been shown that LPS 
promotes tumour invasion through the TLR4-mediated activation 
of the NF-κB pathway, resulting in the up-regulation of matrix met-
alloproteinase 2 (MMP2) and the β1-integrin subunit.53 Merrell 
et al also showed that stimulation of TLR9-expressing breast cancer 
cells with CpG ODNs dramatically increased their in vitro invasion 
by increasing the activity of MMP13.54 Another in vitro study sug-
gested that TLR9 agonists can stimulate prostate cancer invasion 
by increasing MMP13 activity.55 Moreover, the interaction of TLR2, 
TLR3 and TLR4 with their ligands on human melanoma cells was 
associated with increased cell migration and tumour metastasis.56 
Tumour-secreted miR-21 and miR-29 also act as paracrine ago-
nists of TLRs, which through interacting with either murine TLR7 
or human TLR8 on immune cells transmit signals between tumour 
cells and the microenvironment, leading to regulation of tumour 
metastasis.57,58 The results of our recent studies revealed that TLR4 
blockade using highly selective TLR4 inhibitor TAK-242 suppresses 
ovarian and breast cancer cell invasion through the inhibition of 
EMT. In this study, we showed that not only did TAK-242 reduce the 
enzymatic activity of MMP2 and MMP9 but also down-regulated 
the mRNA expressions of genes involved in both ECM degrada-
tion and EMT-related genes including uPA, uPAR, ZEB1, SNAIL1, 
SNAIL2 (SLUG), CDH2 and β-catenin.59
TLR-mediated angiogenesis
Since vascular endothelial growth factor (VEGF), the main factor 
involved in tumour angiogenesis can be induced by activation of 
TLRs, and it is not surprising to bring up TLRs as potent regulators 
of tumour angiogenesis. The first study that introduced the role of 
TLRs in tumour angiogenesis was conducted on H .pylori–associ-
ated gastric cancer, in which it has shown that H .pylori–induced 
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) expres-
sion enhanced tumour angiogenesis via interacting with TLR2 and 
TLR9.60 Another in vitro study found a direct endothelial stimula-
tory role for LPS in initiating angiogenesis through activation of TLR 
signalling pathways. It became evident that TLR4 promotes colitis-
associated colorectal tumours through phosphorylating epidermal 
growth factor receptor (EGFR) and inducing COX-2 and PGE2.61 In 
another study, TLR4 deficiency protects mice from colitis-associ-
ated neoplasia because of the decreased level of mucosal PGE2.62 
Taken together, these findings are highlighting the importance of 
TLR-associated signals in the regulation of tumour angiogenesis, 
which not only increase the metabolic activity of malignant cells 
but also elevate the risk of tumour invasion to other organs.
TLR-mediated immune escape
Although TLRs are the main player in the regulation of immune 
responses, their aberrant expressions on tumour cells could con-
fer the resistant phenotype to malignant cells against cytotoxic 
effects of lymphocytes through production of some pro-inflam-
matory compounds. During cancer progression in the setting of 
chronic inflammation, integration of TLRs on the tumour cells or 
tumour-infiltrating immune cells and their ligands leads to the se-
cretion of cytokines and chemokines from these cells into the tu-
mour microenvironment. The released cytokines basically suppress 
the immune response, either by impairing the function of APCs, 
T cells and TAA-specific immunity or by recruiting more immune 
suppressive cells to the tumour nidus, leading to the production 
of more inflammatory cytokines that activate cancer-associated fi-
broblasts (CAFs).63 The suppressive cytokines, such as IL-10, IL-6, 
IL-8, VEGF and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) ease immune escape.64 IL-10 also induces tumour-
associated macrophages (TAMs), which in turn release angiogenic 
and lymphangiogenic factors that promote lymphatic metastasis of 
cancer cells.65 The inflammatory cytokines, such as IL-1b, IL-6 and 
PGE2 recruit myeloid-derived suppressor cells (MDSCs) into the 
tumour microenvironment, which aid cancer progression through 
releasing arginase, nitric oxide synthase (NOS) and TGF-β.66 The 
secreted TGF-β activates CAFs, which promote the proliferation 
and progression of cancer through the production of growth fac-
tors and metalloproteinases.67
TLR-mediated metabolic reprogramming in the tumour 
microenvironment
Malignant tumour cells selectively reprogramme their metabolism 
to meet the rapid energy requirements for proliferation, survival 
and metastasis as well as for sustaining the tumour-suppressive 
microenvironment.68 Tumour cells are not the only cells that ben-
efit from metabolic reprogramming, as the other members of the 
tumour microenvironment including DCs, macrophages and T 
cells have shown to have hypoxic and acidotic conditions.68 More 
recent studies suggest that TLRs may directly regulate cell me-
tabolism and thereby have an effect on tumour behaviours and 
functions. TLR3 promotes metabolic reprogramming of head and 
neck carcinoma cells and increases tumour growth and prolifera-
tion. It has been suggested that TLR3 can force tumour cells to 
switch from oxidative phosphorylation (OXPHOS) to glycolysis, 
which subsequently increases the expression of the transcription 
factor HIF-1α and regulates hypoxia.69 In similarity to TLR3, there 
are also some studies reporting the importance of TLR9 in the reg-
ulation of lipid peroxidation in patients with breast carcinoma.70 
In addition to directly affecting tumour metabolic reprogramming, 
TLRs can regulate cancer cell metabolites and indirectly influence 
antitumour immune responses in the tumour microenvironment. 
Through TLR-dependent production of endogenous cAMP, human 
tumour cells can convert naive/effector T cells into senescent T 
cells to induce immune tolerance.71
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3.2 | The anti-tumour activity of TLRs
The complexities of TLRs and their associated signalling pathways 
have portrayed another picture for this cascade as a defender 
against human cancers. It has been suggested that the activation of 
TLRs in the cells could allay immune responses to trigger an anti-
cancer signal (Figure 3).
3.2.1 | A history focusing on anti-tumour 
activity of TLRs
Evidence of antitumour effects of microbial products can be dated 
back to the early 18th century when Deidier (1725) reported that 
infection in cancer patients could be concomitant with the remission 
of malignant diseases. In the 1890s, William B. Coley observed that 
repeated injections of a mixture of bacterial toxins were effective for 
the treatment of cancer patients. Although Coley could not explain 
the mechanism through which the bacteria induced anti-tumour ac-
tivity, the results of this observation introduced bacterial toxins as 
an effective therapeutic strategy against human cancers. In 1943, 
Shear and Turner discovered that LPS had anti-cancer properties.72 
Coley's notion of the antitumour activity of bacterial extracts has 
built a foundation of the theory that bacterial components, such as 
bacterial endo/exotoxins, lipoteichoic acid and bacterial DNA have 
strong antitumour activities through either inducing tumoricidal ef-
fects or enhancing the activation of the innate immune system.73 
This idea was then revisited and explored by many researchers, lead-
ing to an understanding that microbe-derived therapeutics may re-
cruit TLR signalling to exert anti-tumour activity through stimulating 
both innate and adaptive immune responses. TLR-associated signal-
ling and the activation of the downstream mediators, such as type 
F I G U R E  3   The mechanisms through which TLRs orchestrate anti-tumour responses. TLR3 signalling can up-regulate JNK and p38 
which play important roles in regulation and induction of apoptosis. Moreover, TLR3 stimulation can take the control of p53 transcription 
and caspase cascade through up-regulation of IFN-γ. TLR9 activation, on the other hand, up-regulates Bax which inserts into mitochondria 
membrane and makes it permeable to cytochrome C that is capable to initiate caspase-dependent apoptosis. Because of the high-level 
expression of TLRs on DCs, TLR agonists can make these cells present TAAs to T cells optimally. Activated DCs, in turn, could activate NK 
cells by secretion of type I IFNs and using INAM-INAM interaction. On the other hand, activation of MDSCs by TLR7, 9 agonists inhibit their 
suppressor effects, leading to their maturation into APCs with the ability to elicit T cell anti-tumour response. Moreover, stimulation of TLRs 
not only stops inhibitory functions of Tregs via IL-6 induction but also suppresses their recruitment to the tumour microenvironment. Finally, 
stimulation of TLR3 with poly I:C up-regulates TNF-α that induces M1 macrophage phenotype with an important role in tumour regression
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I IFNs, could be therapeutically used to shift the balance from im-
munotolerance to antitumour effects. TLR7 agonists and IFN-alpha 
have also shown promising therapeutic results in melanoma, basal 
cell cancer, renal cell cancer and hairy cell leukaemia.74 These find-
ings aroused a stream of studies concentrating on the anti-tumour 
activities for TLRs.
3.2.2 | The mechanisms through which 
TLRs orchestrate anti-tumour responses
The results of deep molecular investigations proposed that TLRs 
could exert their anti-tumour activity either by regulation of the ap-
optotic pathway or through modulating the activity of the immune 
cells, such as DCs, NK cells and T lymphocytes.
The ability of TLRs in induction of apoptotic cell death in cancer 
cells
Although multiple lines of evidence emphasized the anti-apoptotic 
effects of TLRs, in many cases, there are conflicting results. TLR9 
is the best example of this controversy as the apoptosis-inducing 
capacity of this receptor is mediated through the mitochondrial-
dependent pathway. It has been shown that CpG-DNA–mediated 
activation of TLR9 not only increased the expression of Bax but also 
induced caspase-dependent apoptotic cell death in murine mac-
rophages.75 Moreover, the interaction of TLR3 with dsRNA triggers 
a cascade to activate a wide range of downstream axes, such as p38, 
JNK and IFN regulatory factors, which in turn regulate apoptosis in 
cancer cells.76 TLR3-poly I:C interaction also enhances the thera-
peutic value of the conventional antitumour agent cycloheximide 
in different human and murine tumour cell lines through increasing 
the production of IFN-γ, a well-known cytokine which its associa-
tion with caspase and p53 has been previously well-established.77
Immunomodulation through TLR signalling
Through inducing the cytotoxic signalling, mobilizing NK and 
T cells, and producing the anti-tumour antibodies, the immune 
system could conveniently take hold of cancer cells. Being the 
most important components of the immune system and being ex-
pressed in most, if not all, immune cells, it is not surprising that 
TLRs may play a part in the anti-cancer effects of the immune 
system. As professional APCs, which express a large number of 
TLRs, DCs are at the interface of innate and adaptive immune re-
sponses. Activated DCs amplify immune system-induced anti-tu-
mour responses through presenting tumour antigens to cytotoxic 
T lymphocytes. The activation of DCs could be mediated through 
several mechanisms, but one of the most important ones is the 
stimulation of the TLR signalling pathway. TLR5, TLR7 and TLR9 
are the best examples of TLRs that could reinforce the anti-tumour 
activity of DCs.78 Not only TLRs could convert mature MDSCs to 
professional APCs and facilitate the presentation of tumour anti-
gens to the cytotoxic T cells but also could suppress the activity 
of Tregs through secretion of IL-6.79 TLR-activated DCs could also 
make a partnership with NK cells through INAM interaction and 
secreting type I IFNs to activate them that leads to eradication of 
malignant cells.80 It has been reported that TLR3 stimulation in a 
mouse model of melanoma repressed the progression of tumour 
through myeloid DC-mediated activation of NK cells.81 It should 
be noted that all TLRs do not exert their anti-tumour activities 
through regulation of DCs. For example, TLR8 could either directly 
suppress the activity of Tregs or reduce the recruitment of Tregs 
to the tumour cells through secreting CCL22.82
Additional mechanisms through which TLRs exert antitumour 
effects
Converting tumour-supporting macrophages to tumour suppres-
sors that produce inflammatory cytokines and promote M1 polari-
zation is another suggested mechanism that has been attributed to 
the anti-tumour activity of poly I:C-activated TLR3. This response is 
mediated by TNF-α through a MyD88-independent pathway.83 TLR9 
agonists can also exert antitumour effects through suppression of 
angiogenesis. It is likely that the production of IFNs, such as IFN-
alpha, also plays a key role in both anti-angiogenetic and tumour-
suppressive effects of TLRs.84
4  | CONCLUSION AND FUTURE 
PERSPEC TIVE
In many cases, cancer cells mimic many characteristics of immune 
cells. So, under the mask of these cells, neoplastic cells communicate 
and modulate the immune system for their own survival and growth. 
Despite several reports shedding light on the association between 
TLRs and the incidence of tumorigenesis, a considerable number of 
questions remained unanswered about the precise mechanisms of 
these receptors in cancer development. Given this, further explora-
tion and more precise understanding concerning the role of TLRs in 
the maintenance of cancer cells are required to increase the current 
knowledge about their participation in tumour biology. These find-
ings could also shed more light on the molecular basis of innate im-
munity, tumorigenesis and cancer biology, which all together could 
start a new chapter in the modern understating of cancer and its 
treatment strategies.
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